Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 4/2016

01-03-2016 | Letter to the Editor

Toxic epidermal necrolysis in adult T cell leukemia/lymphoma treated with mogamulizumab

Authors: Kazuna Tanba, Nobuhiko Uoshima, Hitoji Uchiyama, Eri Kawata, Reiko Isa, Junko Yamaguchi, Yasuhiko Tsutsumi, Teruaki Akaogi, Yutaka Kobayashi, Kanade Katsura, Junya Kuroda, Masafumi Taniwaki

Published in: Annals of Hematology | Issue 4/2016

Login to get access

Excerpt

Dear Editor, …
Literature
1.
2.
Ishida T, Ito A, Sato F, Kusumoto S, Iida S, Inagaki H, Morita A, Akinaga S, Ueda R (2013) Stevens-Johnson syndrome associated with mogamulizumab treatment of adult T-cell leukemia/lymphoma. Cancer Sci 104:647–650. doi:10.​1111/​cas.​12116 CrossRefPubMed
3.
Schwartz RA, McDonough PH, Lee BW (2013) Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol 69:173. doi:10.​1016/​j.​jaad.​2013.​05.​003, e1-13 PubMed
4.
Azukizawa H, Sano S, Kosaka H, Sumikawa Y, Itami S (2005) Prevention of toxic epidermal necrolysis by regulatory T cells. Eur J Immunol 35:1722–1730CrossRefPubMed
5.
Takahashi R, Kano Y, Yamazaki Y, Kimishima M, Mizukawa Y, Shiohara T (2009) Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 182:8071–8079. doi:10.​4049/​jimmunol.​0804002 CrossRefPubMed
6.
Shiratori S, Ohigashi H, Ito S, Kudo K, Adachi M, Minamimoto T, Kato J, Osai Y, Tsutsumi Y, Teshima T (2015) Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti-CC chemokine receptor 4 antibody for the treatment of adult T cell leukaemia/lymphoma. Hematol Oncol. in print. doi: 10.​1002/​hon.​2242.
Metadata
Title
Toxic epidermal necrolysis in adult T cell leukemia/lymphoma treated with mogamulizumab
Authors
Kazuna Tanba
Nobuhiko Uoshima
Hitoji Uchiyama
Eri Kawata
Reiko Isa
Junko Yamaguchi
Yasuhiko Tsutsumi
Teruaki Akaogi
Yutaka Kobayashi
Kanade Katsura
Junya Kuroda
Masafumi Taniwaki
Publication date
01-03-2016
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 4/2016
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-016-2594-1

Other articles of this Issue 4/2016

Annals of Hematology 4/2016 Go to the issue

Letter to the Editor

Necrobiotic xanthogranuloma associated with monoclonal gammopathy: successful treatment with lenalidomide and dexamethasone

Letter to the Editor

Short and long-term prognostic implications of a low embolic burden in oncology patients diagnosed with symptomatic pulmonary embolism

Original Article

Peripheral T cell lymphomas in elderly patients: a retrospective analysis from the Hematology Association of South East Korea (HASEK)

Original Article

Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review

Review Article

Purification of hematopoietic stem cells from bone marrow

Original Article

Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits